Versant Ventures, Eli Lilly, and a handful of other investors announced Monday that they have poured $100 million into a new startup devoted to solving a gene therapy challenge that has ensnared many well-funded academics and biotechs before it.
The company, called Seawolf Therapeutics, is trying to deliver genes to patients without the use of viruses. In addition to the $100 million fundraising, Sanofi has also inked a partnership with the company.
Viruses have proven to be powerful gene delivery drones in several rare diseases, and they are being tested in hundreds of trials. But they come with drawbacks. A patient can only ever receive a single dose, after which they develop antibodies against the virus. And at high doses the treatments can have serious side effects.

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Source: www.statnews.com



